The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.
B. Schultheis
No relevant relationships to disclose
G. Folprecht
Consultant or Advisory Role - Merck Serono; Roche/Genentech
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Merck Serono
J. Kuhlmann
No relevant relationships to disclose
R. Ehrenberg
No relevant relationships to disclose
U. T. Hacker
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis; Roche
Research Funding - Bayer
C. Kohne
No relevant relationships to disclose
M. Kornacker
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
O. Boix
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
T. Lin
Employment or Leadership Position - Bayer
J. Krauss
No relevant relationships to disclose
R. Fischer
No relevant relationships to disclose
S. Hamann
No relevant relationships to disclose
D. Strumberg
Consultant or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
K. B. Mross
No relevant relationships to disclose